Victoria Chang, MD
Neurology · San Francisco, CANPI 1659833283
Payments from drug & device makers
What this record shows
This record is dominated by grants: $12,500 of the $17,262 with a category attached, or 72.4%. Boston Scientific accounts for 74.8% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $10,048 and has fallen 93.4% since, to $662 in 2025.
Across 55 payments — averaging $313.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$13K
- Medtronic$2K
- Amneal Pharmaceuticals LLC$1K
- Supernus Pharmaceuticals, Inc.$570
- Teva Pharmaceuticals USA, Inc.$111
- AbbVie$28
- plus $20 from 1 others
What the payments were for
- Consulting fees$7454%
- Grants$12,50072%
- Travel & lodging$1,3148%
- Food & beverage$2,70416%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 7 | $12,912 |
| Medtronic | 38 | $2,459 |
| Amneal Pharmaceuticals LLC | 4 | $1,161 |
| Supernus Pharmaceuticals, Inc. | 3 | $570 |
| Teva Pharmaceuticals USA, Inc. | 1 | $111 |
| AbbVie | 1 | $28 |
| Lilly USA, LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERCISE$12,500
- RYTARY$1,069
- PERCEPT PC BRAINSENSE$735
- ACCOLADE SR$330
- QELBREE$290
- Austedo XR$111
How this compares
$17,262 in reported general payments places this provider in the 80th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carbidopa-LevodopaCarbidopa/Levodopa | 66 | $3,413 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 24 | $861 |
| Propranolol Hcl | 14 | $295 |
| Donepezil Hcl | 24 | $157 |
| Mirtazapine | 14 | $118 |
| Zonisamide | 16 | $106 |
Paid to pharmacies, not to this prescriber.
Other neurology in San Francisco
- S Claiborne JohnstonSan Francisco$576K
- Armen MoughamianSan Francisco$554K
- Scott ZamvilSan Francisco$447K
- Bruce CreeSan Francisco$412K
- Kenneth LaxerSan Francisco$379K
- Jonathan KatzSan Francisco$294K
- Nada HindiyehSan Francisco$268K
- Douglas GoodinSan Francisco$227K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.